<table border="1" id="t31496141280" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4:  Clinically Significant Drug Interactions with OXYCONTIN</caption>
<colgroup>
<col width="24*"></col>
<col width="73*"></col>
</colgroup>
<tbody>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Inhibitors
of CYP3A4 and CYP2D6</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">The concomitant
use of OXYCONTIN and CYP3A4 inhibitors can increase the plasma concentration
of oxycodone, resulting in increased or prolonged opioid effects.
These effects could be more pronounced with concomitant use of OXYCONTIN
and CYP2D6 and CYP3A4 inhibitors, particularly when an inhibitor is
added after a stable dose of OXYCONTIN is achieved <content stylecode="italics">[see Warnings
and Precautions (<linkhtml href="#Section_5.4">5.4</linkhtml>)]</content>.<br/>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor
decline, the oxycodone plasma concentration will decrease <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, resulting in decreased opioid efficacy or a withdrawal
syndrome in patients who had developed physical dependence to oxycodone.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">If concomitant
use is necessary, consider dosage reduction of OXYCONTIN until stable
drug effects are achieved. Monitor patients for respiratory depression
and sedation at frequent intervals.<br/>If a CYP3A4 inhibitor
is discontinued, consider increasing the OXYCONTIN dosage until stable
drug effects are achieved.  Monitor for signs of opioid withdrawal.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Macrolide antibiotics
(e.g., erythromycin), azole-antifungal agents (e.g. ketoconazole),
protease inhibitors (e.g., ritonavir)</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">CYP3A4 Inducers</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">The concomitant
use of OXYCONTIN and CYP3A4 inducers can decrease the plasma concentration
of oxycodone <content stylecode="italics">[see Clinical Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, resulting in decreased
efficacy or onset of a withdrawal syndrome in patients who have developed
physical dependence to oxycodone <content stylecode="italics">[see Warnings and Precautions
(<linkhtml href="#Section_5.4">5.4</linkhtml>)]</content>.<br/>After
stopping a CYP3A4 inducer, as the effects of the inducer decline,
the oxycodone plasma concentration will increase <content stylecode="italics">[see Clinical
Pharmacology (<linkhtml href="#Section_12.3">12.3</linkhtml>)]</content>, which
could increase or prolong both the therapeutic effects and adverse
reactions, and may cause serious respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
<br/>
<br/>
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">If concomitant
use is necessary, consider increasing the OXYCONTIN dosage until stable
drug effects are achieved. Monitor for signs of opioid withdrawal.
If a CYP3A4 inducer is discontinued, consider OXYCONTIN dosage reduction
and monitor for signs of respiratory depression.<br/>Rifampin,
carbamazepine, phenytoin</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Benzodiazepines
and Other Central Nervous System (CNS) Depressants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Due to additive
pharmacologic effect, the concomitant use of benzodiazepines or other
CNS depressants, including alcohol, can increase the risk of hypotension,
respiratory depression, profound sedation, coma, and death.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Reserve concomitant
prescribing of these drugs for use in patients for whom alternative
treatment options are inadequate. Limit dosages and durations to the
minimum required. Follow patients closely for signs of respiratory
depression and sedation <content stylecode="italics">[see Dosage and Administration (<linkhtml href="#Section_2.6">2.6</linkhtml>), Warnings and Precautions (<linkhtml href="#Section_5.5">5.5</linkhtml>)]</content>.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Benzodiazepines
and other sedatives/hypnotics, anxiolytics,  tranquilizers, muscle
relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Serotonergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">The concomitant
use of opioids with other drugs that affect the serotonergic neurotransmitter
system has resulted in serotonin syndrome.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">If concomitant
use is warranted, carefully observe the patient, particularly during
treatment initiation and dose adjustment.  Discontinue OXYCONTIN if
serotonin syndrome is suspected.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Selective serotonin
reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake
inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3
receptor antagonists, drugs that affect the serotonin neurotransmitter
system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase
(MAO) inhibitors (those intended to treat psychiatric disorders and
also others, such as linezolid and intravenous methylene blue).</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Monoamine
Oxidase Inhibitors (MAOIs)</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">MAOI interactions
with opioids may manifest as serotonin syndrome or opioid toxicity
(e.g., respiratory depression, coma) <content stylecode="italics">[see Warnings and Precautions
(<linkhtml href="#Section_5.2">5.2</linkhtml>)].</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">The use of OXYCONTIN
is not recommended for patients taking MAOIs or within 14 days of
stopping such treatment.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">phenelzine, tranylcypromine,
linezolid</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Mixed Agonist/Antagonist
and Partial Agonist Opioid Analgesics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">May reduce the
analgesic effect of OXYCONTIN and/or precipitate withdrawal symptoms.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Avoid concomitant
use.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Examples:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">butorphanol, nalbuphine,
pentazocine, buprenorphine</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Muscle Relaxants</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Oxycodone may enhance
the neuromuscular blocking action of skeletal muscle relaxants and
produce an increased degree of respiratory depression.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Monitor patients
for signs of respiratory depression that may be greater than otherwise
expected and decrease the dosage of OXYCONTIN and/or the muscle relaxant
as necessary.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Diuretics</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Opioids can reduce
the efficacy of diuretics by inducing the release of antidiuretic
hormone.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Monitor patients
for signs of diminished diuresis and/or effects on blood pressure
and increase the dosage of the diuretic as needed.</td>
</tr>
<tr>
<td colspan="2" stylecode="Toprule Botrule Rrule Lrule">
<content stylecode="bold">Anticholinergic
Drugs</content>
</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Clinical Impact:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">The concomitant
use of anticholinergic drugs may increase risk of urinary retention
and/or severe constipation, which may lead to paralytic ileus.</td>
</tr>
<tr>
<td align="right" stylecode="Toprule Botrule Rrule Lrule" valign="top">
<content stylecode="italics">Intervention:</content>
</td>
<td stylecode="Toprule Botrule Rrule Lrule" valign="top">Monitor patients
for signs of urinary retention or reduced gastric motility when OXYCONTIN
is used concomitantly with anticholinergic drugs.</td>
</tr>
</tbody>
</table>